GSK to buy asthma drug developer for up to $1.4 billion in pipeline push

The British pharmaceutical giant’s deal will give it access to Aiolos’ AIO-001 asthma treatment

Previous post The history of tech holds a big warning for investors in Nvidia, Microsoft and other AI plays, says this storied investor
Next post S&P 500 futures dip as Samsung warning damps technology stocks